MedTrace Logo

Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.

NCT05990894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2025-07-11

No results posted yet for this study

Summary

The cohort study aims to evaluate the efficacy and safety of steroids combined with anticoagulant therapy compared to standard anticoagulant therapy in acute/subacute severe cerebral venous thrombosis.

Conditions

  • Cerebral Venous Thrombosis

Interventions

DRUG

Methylprednisolone

In the steroid therapy group, patients received standard treatment plus steroid therapy. Steroid therapy protocol is as follows: 500 mg methylprednisolone once a day, intravenous drip for 3 days, then reduced to 80 mg once a day, intravenous drip for 5 days, and changed to oral methylprednisolone/prednisone 1 mg per kilogram body weight, gradually tapered off by a dose of 10 mg per week.

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Jiangang Duan, MD, PhD · Xuanwu Hospital, Beijing

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05990894 on ClinicalTrials.gov